Reported about 17 hours ago
Omnicom Group and Achieve Life Sciences have entered a strategic partnership to spearhead the US launch of cytisinicline, a new treatment for nicotine dependence. This collaboration aims to leverage AI technology and a data-driven approach for effective marketing and engagement with healthcare professionals and patients. With a unified team from various specialized agencies, the project seeks to revolutionize biopharma commercialization.
Source: YAHOO